ANCR

ncRNA information

ncRNA name

ANCR

Specific or universal ncRNAs

Universal ncRNAs

Class

Long noncoding RNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

Not available

Cancer information

Cancer name

Osteosarcoma

Cancer site

qRT-PCR,Western blot

Treatment information

Treatment type

Chemotherapy

Drug

Adriamycin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

SiRNA-mediated knockdown of ANCR decreased in vitro proliferation, while increasing sensitivity to Dox treatment in the KHOS-DR/U2OS-DR cells

Tissue resource

osteosarcoma doxorubicin-resistant cell lines U2OS-DR

osteosarcoma patients chemoresistant and chemosensitive to adriamycin

osteosarcoma doxorubicin-sensitive cell lines KHOS

osteosarcoma doxorubicin-sensitive cell lines U2OS

osteosarcoma doxorubicin-resistant cell lines KHOS-DR

Experiment

None


Institute

West China Hospital 

Massachusetts General Hospital and Harvard Medical School

Country

China

United States

Continent

Asia

North Amercian